

## LAB LOCATIONS

### California

Integrated Oncology  
2601 Campus Drive  
Irvine, California 92612  
(800) 710-1800  
Fax (949) 450-0146

Monogram Biosciences  
345 Oyster Point Blvd,  
South San Francisco, CA 94080  
(800) 777-0177

### New York

Integrated Oncology  
521 West 57th Street, Sixth Floor  
New York, New York 10019  
(800) 447-8881  
Fax (212) 258-2137

### North Carolina

LabCorp Center for Molecular  
Biology and Pathology  
1912 Alexander Drive  
Research Triangle Park,  
North Carolina 27709  
(800) 345-4363  
Fax (919) 361-7201

### Tennessee

Integrated Oncology  
201 Summit View Drive, Suite 100  
Brentwood, Tennessee 37027  
(800) 874-8532  
Fax (615) 370-8074



HERmark® is a registered trademark and service mark, and VeraTag® is a registered service mark of Laboratory Corporation of America® Holdings.  
©2012 Laboratory Corporation of America® Holdings. All rights reserved.  
onc-701-v1-1212

## Quantitative HER3 protein expression and PIK3CA mutation status in matched samples from primary and metastatic breast cancer tissues and correlation with time to recurrence

J Sperinde<sup>1</sup>, J Lara<sup>2</sup>, R Michaelson<sup>2</sup>, X Sun<sup>2</sup>, P Conte<sup>3</sup>, V Guarneri<sup>3</sup>, E Barbieri<sup>3</sup>, SM Ali<sup>4,5</sup>, K Leitzel<sup>4</sup>, J Weidler<sup>1</sup>, Y Lie<sup>1</sup>, J Cook<sup>1</sup>, M Haddad<sup>1</sup>, A Paquet<sup>1</sup>, J Winslow<sup>1</sup>, J Howitt<sup>6</sup>, L Hurley<sup>6</sup>, M Eisenberg<sup>6</sup>, C Petropoulos<sup>1</sup>, W Huang<sup>1</sup> and A Lipton<sup>4</sup>

<sup>1</sup>Monogram Biosciences Inc., South San Francisco, CA; <sup>2</sup>Saint Barnabas Medical Center, Livingston, NJ; <sup>3</sup>University of Modena, Modena, Italy; <sup>4</sup>Penn State / Hershey Medical Center, Hershey, PA; <sup>5</sup>Lebanon VA Medical Center, Lebanon, PA; <sup>6</sup>Laboratory Corporation of America, Research Triangle Park, NC

### Abstract

**Background:** HER3 is thought to play a prominent role in resistance to HER2-directed breast cancer therapies. Recent data suggest that HER3 levels also influence HER2-normal breast tumor biology. HER3 and PI3K signaling are linked in that in HER3 signaling activates PI3K and inhibition of PI3K activity can upregulate HER3 expression. Here, we measured quantitative HER3 protein expression levels and PIK3CA mutation status in matched tissues from the primary tumor and site of metastasis to assess correlations with time to recurrence.

**Methods:** 44 pairs (8 HER2+ by HERmark®) of matched tissues from the primary tumor and the site of metastasis were evaluated for HER3 protein expression using a sensitive, quantitative assay for HER3 protein expression in FFPE tissue sections (VeraTag®). Matched samples were also evaluated for quantitative HER2 expression (HERmark) and for PIK3CA mutations at exon 9 (E542K and E545K) and exon 20 (H1047R).

**Results:** HER3 protein expression at the metastatic site was largely independent of HER3 levels at the primary site (Spearman  $p=0.50$ ) in contrast to HER2 expression (Spearman  $p=0.0004$ ). HER3 expression in the primary tumor correlated with time to recurrence (TTR) (HR=2.0 per 2-fold increase in HER3;  $p<0.0001$ ). Conversely, HER3 expression measured at the site of metastasis was not correlated with TTR ( $p=0.55$ ). Estrogen receptor negative tumors were less likely to have PIK3CA mutations ( $p=0.023$ ). In cases of primary tumors with PIK3CA mutations, no reversions to wild-type PIK3CA were observed in the

metastatic sites. In metastatic tumors, mutations detected in the primary tumor as well as new mutations were observed. A gain of an exon 9 mutation at the metastatic site correlated with shorter TTR (HR=2.5;  $p=0.043$ ). Excluding the 8 samples that were HER2+ by HERmark, longer TTR was observed for patients with PIK3CA mutations in the primary tumor (HR=0.47;  $p=0.042$ ), which is consistent with previous reports. Interestingly, the longer TTR for those with PIK3CA mutations appeared to be dependent on quantitative HER3 protein level (interaction  $p=0.065$ ).

**Conclusions:** HER3 protein expression in matched primary and metastatic breast cancer tissues were unrelated. This may indicate that HER3 protein is influenced by the different tumor microenvironments of the primary and metastatic sites. PIK3CA mutations were either maintained or acquired at metastatic sites. Both low HER3 protein expression and the presence of PIK3CA mutations in the primary tumor but not the metastatic tumor were associated with longer TTR. These observations suggest that HER3 protein expression may be an important prognostic factor for breast cancer progression.

J Sperinde<sup>1</sup>, J Lara<sup>2</sup>, R Michaelson<sup>2</sup>, X Sun<sup>2</sup>, P Conte<sup>3</sup>, V Guarneri<sup>3</sup>, E Barbieri<sup>3</sup>, SM Ali<sup>4,5</sup>, K Leitzel<sup>4</sup>, J Weidler<sup>1</sup>, Y Lie<sup>1</sup>, J Cook<sup>1</sup>, M Haddad<sup>1</sup>, A Paquet<sup>1</sup>, J Winslow<sup>1</sup>, J Howitt<sup>6</sup>, L Hurley<sup>6</sup>, M Eisenberg<sup>6</sup>, C Petropoulos<sup>1</sup>, W Huang<sup>1</sup> and A Lipton<sup>4</sup>

<sup>1</sup>Monogram Biosciences/Integrated Oncology-LabCorp, South San Francisco, CA; <sup>2</sup>Saint Barnabas Medical Center, Livingston, NJ; <sup>3</sup>University of Modena, Modena, Italy; <sup>4</sup>Penn State / Hershey Medical Center, Hershey, PA; <sup>5</sup>Lebanon VA Medical Center, Lebanon, PA; <sup>6</sup>Laboratory Corporation of America, Research Triangle Park, NC.

## Background

HER3 is thought to play a prominent role in resistance to HER2-directed breast cancer therapies. Recent data suggest that HER3 levels also influence HER2-normal breast tumor biology. HER3 and PI3K signaling are linked in that HER3 signaling activates PI3K and inhibition of PI3K activity can upregulate HER3 expression. Here, we measured quantitative HER3 protein expression levels and PIK3CA mutation status in matched tissues from the primary tumor and site of metastasis to assess correlations with time to recurrence.

## Methods

### Quantitative HER2 Assay

Total HER2 protein expression (H2T) was quantified using the HERmark<sup>®</sup> assay (Monogram Biosciences, So. San Francisco, CA) as previously described (Huang et al. *Am J Clin Pathol* 134:303, 2010). H2T was quantified through the release of a fluorescent tag (V for "VeraTag" reporter, see Figure) conjugated to a HER2 monoclonal antibody (mAb). The antibody is paired with a biotinylated second HER2 mAb. An avidin-linked photosensitizer molecule (PM) produces singlet O<sub>2</sub> (<sup>1</sup>O<sub>2</sub>) upon illumination with red light. Signal (V) quantified by capillary electrophoresis is normalized to invasive tumor area on the formalin-fixed, paraffin-embedded (FFPE) tissue section. The continuous H2T results are categorized as HERmark Negative, HERmark Equivocal or HERmark Positive using pre-defined H2T cutoff values (Huang et al. *Am J Clin Pathol* 134:303, 2010).

### Quantitative HER3 Assay

Total HER3 protein expression (H3T) was quantified using the same dual antibody VeraTag platform as described above, but using a proprietary HER3 mAb ("B9A11," Monogram) and a commercial HER3 mAb.


### Mutations of the catalytic domain of PI3 kinase (PIK3CA)

PIK3CA mutation status in exons 9 (E545K and E542K) and 20 (H1047R) was determined using a pyrosequencing method as previously described (Cook J, 2011 ASCO, abstract #582) and performed at the Center for Molecular Biology and Pathology (Laboratory Corporation of America, Research Triangle Park, NC).

### Tissue Samples

66 and 34 pairs of matched primary-metastatic breast cancer tissues were provided by Saint Barnabas Medical Center, Livingston, NJ and University of Modena, Modena, Italy, respectively. Tissue samples with inadequate amount of invasive tumor for either HERmark or PIK3CA mutation testing were excluded. Cases of bone metastasis were also excluded due to uncertain impact of fixation of bone samples on HER2 testing. A total of 44 pairs of matched FFPE samples had valid results for both HERmark and PIK3CA mutation testing and were included in the final analysis.


## Quantitative HER2 Assay



## Patient/Tissue Characteristics

Characteristic	No. (range or %)
Median age at diagnosis	53 (35–82 yr)
Median months from primary to metastasis	61 (1.3–137 mo)
HERmark HER2 status for primary tumor	
Negative (H2T < 10.5)	33 (75%)
Equivocal (10.5 ≤ H2T ≤ 17.8)	3 (6.8%)
Positive (H2T > 17.8)	8 (18%)
Tumor histological type	
Invasive ductal carcinoma	19 (70%)
Invasive lobular carcinoma	6 (22%)
Other tumor types	2 (7.4%)
N/A (data not available)	17
Tumor grade	
Grade 1 (well differentiated)	1 (2.8%)
Grade 2 (moderately differentiated)	14 (39%)
Grade 3 (poorly differentiated)	21 (58%)
N/A (data not available)	8
Estrogen receptor (ER)	
Negative	12 (29%)
Positive	29 (71%)
N/A (data not available)	3
Metastatic site	
Soft tissue	20 (45%)
Lymph node	5 (11%)
Viscera	13 (30%)
Brain	6 (14%)

## Quantitative HER3 and HER2 in matched primary and metastatic sites



## PIK3CA mutations independent of quantitative HER3

Correlation	p-value
primary H3T α PIK3CA mutation in primary	0.8
primary H3T α PIK3CA mutation in met	0.29
primary H3T α PIK3CA mutation gain from primary to met	0.11
met H3T α PIK3CA mutation in primary	0.5
met H3T α PIK3CA mutation in met	1.0
met H3T α PIK3CA mutation gain from primary to met	0.9

## PIK3CA mutations and ER status


PIK3CA mutation status	ER status	
	negative	positive
wild type (primary and met)	8	9
mutant (primary or met)	2	19

Fisher p = 0.023


## Time to Recurrence (TTR) by quantitative HER3 and PIK3CA mutation status

### TTR correlated with PIK3CA mutations only in the primary tumor

- In metastases, all mutations detected in the primary tumor plus new mutations were observed.
- A gain of exon 9 mutation correlated with shorter TTR (p=0.043).



### TTR correlated with quantitative HER3 only in the primary tumor



- Continuous H3T in the primary tumor correlated with shorter TTR (p=0.0008).

- There was a possible interaction of PIK3CA mutation with continuous H3T (p=0.065) where PIK3CA mutations in the primary tumor were correlated with TTR only in low-H3T cases

Continuous variable	TTR	
	HR	p-value
log <sub>2</sub> (H3T primary)	2.0	3e-5
log <sub>2</sub> (H3T met)	0.92	0.55

## Summary

- H3T in the primary tumor was unrelated to H3T measured at the metastatic site.
- H2T in the primary tumor was correlated with H2T measured at the metastatic site.
- PIK3CA mutation status correlated with ER status but not with H3T.
- PIK3CA mutation status and H3T measured in the primary tumor correlated with TTR.
- The correlation of longer TTR with PIK3CA mutations was largely restricted to cases with low H3T.